AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18277739 — intervention group
Group type: COMPARATOR
Intervention: Colgate Wave manual toothbrush + Colgate Total dentifrice (0.3% triclosan/copolymer dentifrice)
Number of subjects: 179
Study 18277739 — intervention group
Group type: EXPERIMENTAL
Intervention: Wave + Total + Listerine (essential oils rinse)
Number of subjects: 179
Study 18277739 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-B CrossAction manual toothbrush + Crest Pro-Health dentifrice (0.454% stannous fluoride/sodium hexametaphosphate)
Number of subjects: 179
Study 18277739 — intervention group
Group type: EXPERIMENTAL
Intervention: CrossAction + Pro-Health dentifrice + Crest Pro-Health Rinse (0.07% cetylpyridinium chloride rinse)
Number of subjects: 179
Study 18277739 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-B ProfessionalCare Series 8000 power toothbrush + Pro-Health dentifrice
Number of subjects: 179
Study 18277739 — intervention group
Group type: EXPERIMENTAL
Intervention: ProfessionalCare power brush + Pro-Health dentifrice + Oral-B Hummingbird power flosser
Number of subjects: 179
Study 16124951 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0
Study 16124951 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0
Study 14648807 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 24
Study 14648807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10577995 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg
Number of subjects: 844
Study 10577995 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 4 mg, 8 mg, 16 mg
Number of subjects: 844
Study 10577995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 844
Study 10577995 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (all doses)
Number of subjects: 844
Study 8767620 — intervention group
Group type: EXPERIMENTAL
Intervention: defibrotide (400 mg bid)
Number of subjects: 100
Study 8767620 — intervention group
Group type: COMPARATOR
Intervention: heparan-sulfate (40 mg bid)
Number of subjects: 100
Study 1939901 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐ms tones at frequencies of 0.25, 1, 8, or 14 kHz and levels of 30, 60, or 90 dB SPL
Number of subjects: 5
Study 1939901 — intervention group
Group type: EXPERIMENTAL
Intervention: 500‐ms stimuli: a 1‐kHz tone at 90 dB SPL and broadband noise at 63 dB SPL
Number of subjects: 5
Study 7036914 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (group B, n = 11)
Number of subjects: 21
Study 7036914 — intervention group
Group type: COMPARATOR
Intervention: Potassium supplements (group A, n = 10)
Number of subjects: 21
Study 30941817 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 85
Study 30941817 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study 28760277 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Decision Aid (PDA)
Number of subjects: 72
Study 28760277 — intervention group
Group type: COMPARATOR
Intervention: Standard information only (Control)
Number of subjects: 72
Study 26502850 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine maintenance therapy (oral capecitabine 1,250 mg/m2 twice daily on days 1-14 every 3 weeks)
Number of subjects: 72
Study 26502850 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 72
Study 23081843 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin (10 mg) added to contrast medium
Number of subjects: 114
Study 23081843 — intervention group
Group type: COMPARATOR
Intervention: Distilled water added to contrast medium (Control)
Number of subjects: 114
Study 22919877 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole (PPI) 80 mg + 8 mg/h for 72 hours
Number of subjects: 122
Study 20026882 — intervention group
Group type: EXPERIMENTAL
Intervention: WMAS (standing wall stretching with medial arch support)
Number of subjects: 30
Study 20026882 — intervention group
Group type: COMPARATOR
Intervention: WOMAS (standing wall stretching without medial arch support)
Number of subjects: 30
Study 17536226 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 40
Study 17536226 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 40
Study 17536226 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 40
Study 17536226 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 40
Study 11094036 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of [(3)H]L-arginine (100 nCi/min)
Number of subjects: 0
Study 11094036 — intervention group
Group type: EXPERIMENTAL
Intervention: [(3)H]L-arginine uptake by peripheral blood mononuclear cells (PBMCs)
Number of subjects: 0
Study 11094036 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA expression for the cationic amino acid transporter CAT-1
Number of subjects: 0
Study 8985768 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin
Number of subjects: 20
Study 8985768 — intervention group
Group type: COMPARATOR
Intervention: Nasal carriage of Staphylococcus aureus
Number of subjects: 20
Study 1618242 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release nicardipine 45-60 mg/d
Number of subjects: 42
Study 1618242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 6367689 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant drug treatment
Number of subjects: 0
Study 6367689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30549321 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored repositioning and turning and repositioning system
Number of subjects: 227
Study 30549321 — intervention group
Group type: EXPERIMENTAL
Intervention: Turning and repositioning system
Number of subjects: 227
Study 30549321 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 227
Study 29342393 — intervention group
Group type: COMPARATOR
Intervention: Cytoreductive surgery without HIPEC
Number of subjects: 245
Study 29342393 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery with HIPEC
Number of subjects: 245
Study 29342393 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (surgery and surgery-plus-HIPEC)
Number of subjects: 245
Study 27230831 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute stress induction
Number of subjects: 0
Study 27230831 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 24248803 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention intervention (guided by Social Action Theory)
Number of subjects: 9678
Study 24248803 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched control intervention (focused on prevention of relationship violence)
Number of subjects: 9678
Study 24248803 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-level outcomes
Number of subjects: 9678
Study 21996087 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry (IHC) for ERCC1
Number of subjects: 33
Study 21996087 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry (IHC) for TUBB3
Number of subjects: 33
Study 21996087 — intervention group
Group type: COMPARATOR
Intervention: qRT-PCR for ERCC1, BRCA1, RRM1, TUBB3
Number of subjects: 33
Study 21090829 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates (specifically zoledronic acid)
Number of subjects: 0
Study 21090829 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies (cohort and case-control)
Number of subjects: 0
Study 21090829 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analyses
Number of subjects: 0
Study 17929555 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) and aspirin; n = 20
Number of subjects: 40
Study 17929555 — intervention group
Group type: COMPARATOR
Intervention: Control group without GH or aspirin; n = 20
Number of subjects: 40
Study 16261109 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 0
Study 16261109 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 0
Study 12131260 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g/d bovine colostrum + 40 g whey protein concentrate (wpc)
Number of subjects: 42
Study 10068161 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure condition
Number of subjects: 80
Study 10068161 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 80
Study 7675613 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal game condition
Number of subjects: 40
Study 7675613 — intervention group
Group type: COMPARATOR
Intervention: Reverse control condition
Number of subjects: 40
Study 2404650 — intervention group
Group type: EXPERIMENTAL
Intervention: iopentol 300 mg I/ml
Number of subjects: 300
Study 2404650 — intervention group
Group type: COMPARATOR
Intervention: iohexol 300 mg I/ml
Number of subjects: 300
Study 31290747 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day intravenous antibiotics (cefmetazole and metronidazole)
Number of subjects: 176
Study 31290747 — intervention group
Group type: COMPARATOR
Intervention: 4-day intravenous and oral antibiotics (cefmetazole and metronidazole)
Number of subjects: 176
Study 31290747 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day intravenous antibiotics
Number of subjects: 176
Study 31290747 — intervention group
Group type: COMPARATOR
Intervention: 4-day intravenous and oral antibiotics
Number of subjects: 176
Study 28850408 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA)
Number of subjects: 56
Study 28850408 — intervention group
Group type: COMPARATOR
Intervention: Femoral nerve block (FNB)
Number of subjects: 56
Study 26070468 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized intensive staged-based nutrition education by a dedicated renal dietitian
Number of subjects: 394
Study 26070468 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 394
Study 26070468 — intervention group
Group type: COMPARATOR
Intervention: Nutrition education from general hospital dietitians
Number of subjects: 394
Study 23471413 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐39588146 (15 ng/kg/min)
Number of subjects: 62
Study 23471413 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐39588146 (30 ng/kg/min)
Number of subjects: 62
Study 23471413 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐39588146 (any dose)
Number of subjects: 62
Study 23471413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 21290111 — intervention group
Group type: EXPERIMENTAL
Intervention: PCL-retaining (PCLR) prosthesis
Number of subjects: 108
Study 21290111 — intervention group
Group type: COMPARATOR
Intervention: PCL-sacrificing (PCLS) prosthesis
Number of subjects: 108
Study 20803860 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine 7.5 mg (Group I)
Number of subjects: 80
Study 20803860 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine 10 mg (Group II)
Number of subjects: 80
Study 20803860 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine 12.5 mg (Group III)
Number of subjects: 80
Study 20803860 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine 15 mg (Group IV)
Number of subjects: 80
Study 17956835 — intervention group
Group type: EXPERIMENTAL
Intervention: didanosine/stavudine (n = 8)
Number of subjects: 19
Study 17956835 — intervention group
Group type: COMPARATOR
Intervention: didanosine/lamivudine plus nevirapine (n = 7)
Number of subjects: 19
Study 17956835 — intervention group
Group type: COMPARATOR
Intervention: didanosine/lamivudine plus ritonavir-boosted saquinavir (n = 4)
Number of subjects: 19
Study 16400889 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based education, cockroach and rodent extermination, mattress and pillow encasings, high-efficiency particulate air cleaner
Number of subjects: 100
Study 16400889 — intervention group
Group type: COMPARATOR
Intervention: Control group (treated at the end of the 1-year trial)
Number of subjects: 100
Study 12507680 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (Regulatory enforcement, Education, Peer influence)
Number of subjects: 68
Study 12507680 — intervention group
Group type: COMPARATOR
Intervention: Control pharmacies
Number of subjects: 68
Study 9585287 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 5 microg/kg (CLON)
Number of subjects: 88
Study 9585287 — intervention group
Group type: COMPARATOR
Intervention: No premedication (CONT)
Number of subjects: 88
Study 7707407 — intervention group
Group type: COMPARATOR
Intervention: Standard radiation therapy (60 Gy delivered at 2 Gy per fraction, 5 days a week, over a 6-week period)
Number of subjects: 452
Study 7707407 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (cisplatin 100 mg/m2 on days 1 and 29, vinblastine 5 mg/m2 per week for 5 weeks) followed by standard radiation therapy (starting on day 50)
Number of subjects: 452
Study 7707407 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy (69.6 Gy delivered at 1.2 Gy per fraction twice daily)
Number of subjects: 452
Study 2543337 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (1.8% NaCl)
Number of subjects: 20
Study 2543337 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (NS)
Number of subjects: 20
Study 344086 — intervention group
Group type: EXPERIMENTAL
Intervention: Serenace
Number of subjects: 25
Study 344086 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 25
Study 31491583 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + BA + CM
Number of subjects: 120
Study 31491583 — intervention group
Group type: COMPARATOR
Intervention: CBT + BA
Number of subjects: 120
Study 27255407 — intervention group
Group type: EXPERIMENTAL
Intervention: Inex Pediculicide Soap®
Number of subjects: 45
Study 27255407 — intervention group
Group type: COMPARATOR
Intervention: Paranix®
Number of subjects: 45
Study 25351561 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of daidzein
Number of subjects: 165
Study 25351561 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of genistein
Number of subjects: 165
Study 25351561 — intervention group
Group type: COMPARATOR
Intervention: 10 g of soy protein plus no addition
Number of subjects: 165
Study 23154216 — intervention group
Group type: COMPARATOR
Intervention: Modification of school cafeteria environment
Number of subjects: 0
Study 23154216 — intervention group
Group type: COMPARATOR
Intervention: Cafeteria modification program
Number of subjects: 0
Study 21624774 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Sleep Deprivation (T-SD) for 2 consecutive nights
Number of subjects: 28
Study 21624774 — intervention group
Group type: EXPERIMENTAL
Intervention: REM Sleep Deprivation (REM-SD) for 4 consecutive nights
Number of subjects: 28
Study 21624774 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL) group
Number of subjects: 28
Study 19322731 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBTC)
Number of subjects: 459
Study 19322731 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 459
Study 17041809 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endurance and strength training for 4 months after initial 4 months of training
Number of subjects: 20
Study 17041809 — intervention group
Group type: COMPARATOR
Intervention: Control group (ceased training after 4 months)
Number of subjects: 20
Study 12919161 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk supplementation during pregnancy and childhood
Number of subjects: 951
Study 11194695 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help booklet promoting dietary change delivered by physicians
Number of subjects: 935
Study 11194695 — intervention group
Group type: COMPARATOR
Intervention: Self-help booklet promoting dietary change delivered by clinic staff
Number of subjects: 935
Study 9062602 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine (0.1 ml, 10 mg/ml) combined with lidocaine (3 ml, 2%)
Number of subjects: 80
Study 9062602 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (0.1 ml) combined with lidocaine (3 ml, 2%)
Number of subjects: 80
Study 7870908 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrahydroaminoacridine (THA)
Number of subjects: 89
Study 7870908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 3739810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehearsal
Number of subjects: 53
Study 3739810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue avoidance
Number of subjects: 53
Study 3739810 — intervention group
Group type: COMPARATOR
Intervention: Social pressure
Number of subjects: 53
Study 30227890 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimised participant information brochure and cover letter
Number of subjects: 2262
Study 30227890 — intervention group
Group type: COMPARATOR
Intervention: Control group: original participant information brochure and accompanying letter
Number of subjects: 2262
Study 27912943 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed yoga (HSY)
Number of subjects: 0
Study 27912943 — intervention group
Group type: COMPARATOR
Intervention: Standard-speed yoga (SSY)
Number of subjects: 0
Study 24621557 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial exclusion criteria
Number of subjects: 15379
Study 24621557 — intervention group
Group type: EXPERIMENTAL
Intervention: Other criteria (including comorbid conditions)
Number of subjects: 15379
Study 24621557 — intervention group
Group type: EXPERIMENTAL
Intervention: No reason provided
Number of subjects: 15379
Study 22734388 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupotomy
Number of subjects: 90
Study 22734388 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Pricking
Number of subjects: 90
Study 22734388 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Therapy (Acupotomy + Blood Pricking)
Number of subjects: 90
Study 20668051 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1500 mg Ca/d from 20 weeks of gestation until delivery)
Number of subjects: 389
Study 20668051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 389
Study 18346640 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-CD25 monoclonal antibody (Daclizumab)
Number of subjects: 21
Study 18346640 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 15866629 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (20 mg before transplantation and 20 mg on day 4)
Number of subjects: 87
Study 15866629 — intervention group
Group type: COMPARATOR
Intervention: Control group (no basiliximab)
Number of subjects: 87
Study 15866629 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (when excluding non-heart-beating donors)
Number of subjects: 87
Study 15866629 — intervention group
Group type: COMPARATOR
Intervention: Control group (when excluding non-heart-beating donors)
Number of subjects: 87
Study 15866629 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 87
Study 11956046 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 200 microg qid for 1 week
Number of subjects: 8
Study 11956046 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 week
Number of subjects: 8
Study 11956046 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 100, 100, and 200 microg inhaled at 5-minute intervals after exercise
Number of subjects: 8
Study 9557918 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 245
Study 9557918 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 245
Study 7636536 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexverapamil 120 mg/m2 plus vinblastine 0.11 mg/kg IV on days 1 and 2 every 21 days
Number of subjects: 23
Study 7636536 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexverapamil 180 mg/m2 plus dexamethasone plus vinblastine 0.11 mg/kg IV on days 1 and 2 every 21 days
Number of subjects: 23
Study 2129695 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling and follow-up at 2 and 3 weeks and at 3 and 6 months (group B)
Number of subjects: 152
Study 2129695 — intervention group
Group type: COMPARATOR
Intervention: Counseling alone (group A)
Number of subjects: 152
Study 2129695 — intervention group
Group type: COMPARATOR
Intervention: Counseling by smoking physicians
Number of subjects: 152
Study 2129695 — intervention group
Group type: COMPARATOR
Intervention: Counseling by non-smoking physicians
Number of subjects: 152
Study 326013 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Gm. of ASA daily
Number of subjects: 148
Study 326013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 326013 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA
Number of subjects: 148
Study 29373530 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber scone with RS4
Number of subjects: 0
Study 29373530 — intervention group
Group type: COMPARATOR
Intervention: Low fiber control scone without RS4
Number of subjects: 0
Study 26536443 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative cognitive-behavioral therapy (CBT)
Number of subjects: 90
Study 26536443 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 90
Study 24308723 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting testosterone undecanoate (TU) 1,000 mg
Number of subjects: 211
Study 24308723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 23346766 — intervention group
Group type: EXPERIMENTAL
Intervention: Group IV (20 ml dexamethasone at 0.5 mg/ml, injected over 30s)
Number of subjects: 400
Study 23346766 — intervention group
Group type: COMPARATOR
Intervention: Group I (2 ml dexamethasone at 5 mg/ml, injected over 5s)
Number of subjects: 400
Study 23346766 — intervention group
Group type: COMPARATOR
Intervention: Group II (4 ml dexamethasone at 2.5 mg/ml, injected over 5s)
Number of subjects: 400
Study 23346766 — intervention group
Group type: COMPARATOR
Intervention: Group III (10 ml dexamethasone at 1 mg/ml, injected over 5s)
Number of subjects: 400
Study 20516633 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate (20 mg/kg/day for 12 weeks)
Number of subjects: 52